Feeds › FDA approvals and clearances
FDA approvals and clearances
New drugs and biologics the FDA approved, and the devices it cleared or approved, from openFDA, with the public companies among the applicants.
About this data
- What it is
- The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
- Who files it
- The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
- How current
- We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
- Terms
- openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
- Worth knowing
- This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
- Not to be confused with
- Clinical trial updates: what sponsors report about their studies, not what the FDA decided.
All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.
Source and freshness · Information, not investment advice (disclaimer).
FDA decisions per day, last 30 days
Brand-name drugs and biologics, with supplements Device clearances and approvals
By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.
Latest FDA decisions
Showing: ticker ALC · Everything
| Decided | Product | ApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed. | DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective. | FDA page |
|---|---|---|---|---|
| Nov 9, 2026 | TROPICAMIDE, MYDRIACYL TROPICAMIDE | ALC Alcon Labs Inc | Generic (ANDA), supplement Labeling | ANDA084306 ↗ |
| Oct 30, 2026 | Clareon Vivity Pro Extended Vision IOLs Extended depth of focus intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Normal 180 Day Track | P190018 ↗ |
| Oct 16, 2026 | BRYTLY APRACLONIDINE HYDROCHLORIDE | ALC Alcon Labs Inc | New drug (NDA) Type 5 - New Formulation or New Manufac… | NDA220341 ↗ |
| Aug 17, 2026 | Clareon Aspheric Hydrophobic Acrylic Intraocular Lens with… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Normal 180 Day Track | P190018 ↗ |
| Aug 4, 2026 | PROVISC Ophthalmic Viscosurgical Device AID, SURGICAL, VISCOELASTIC | ALC Alcon Research, Ltd. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P890047 ↗ |
| Aug 4, 2026 | VISCOAT Ophthalmic Viscosurgical Device; DUOVISC Ophthalmic… AID, SURGICAL, VISCOELASTIC | ALC Alcon Laboratories | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P840064 ↗ |
| Jun 10, 2026 | FLUORESCITE FLUORESCEIN SODIUM | ALC Alcon Labs Inc | New drug (NDA), supplement Labeling | NDA021980 ↗ |
| May 15, 2026 | Clareon Vivity Toric Extended Vision UV Absorbing Hydropho… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Normal 180 Day Track | P190018 ↗ |
| Apr 30, 2026 | AcrySof Single-Piece IOL (SA60AT); AcrySof IQ Aspheric IOL… intraocular lens | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement Normal 180 Day Track | P930014 ↗ |
| Apr 30, 2026 | Clareon Aspheric Hydrophobic Acrylic IOL (SY60WF); Clareon… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Normal 180 Day Track | P190018 ↗ |
| Feb 19, 2026 | Clareon TruPlus Aspheric Hydrophobic Acrylic Intraocular Le… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Real-Time Process | P190018 ↗ |
| Feb 13, 2026 | DAILIES TOTAL1®; DAILIES TOTAL1® Multifocal | ALC Alcon Laboratories, Inc. | Device clearance (510(k)) Traditional | K254052 ↗ |
| Feb 10, 2026 | VISCOAT Ophthalmic Viscosurgical Device AID, SURGICAL, VISCOELASTIC | ALC Alcon Laboratories | Device approval (PMA), supplement Normal 180 Day Track | P840064 ↗ |
| Feb 10, 2026 | UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery Syst… Gases used within eye to place pressure on detached retina | ALC Alcon Research, LLC | Device approval (PMA), supplement Real-Time Process | P230012 ↗ |
| Feb 10, 2026 | UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery Sys… Gases used within eye to place pressure on detached retina | ALC Alcon Research, LLC | Device approval (PMA), supplement Real-Time Process | P220030 ↗ |
| Sep 24, 2025 | LenSx Laser System (8065000944) | ALC Alcon Laboratories, Inc. | Device clearance (510(k)) Special | K252682 ↗ |
| Jun 18, 2025 | AcrySof Posterior Chamber Intraocular Lenses and Delivery S… intraocular lens | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P930014 ↗ |
| Jun 18, 2025 | Clareon Aspheric Hydrophobic Acrylic Intraocular Lenses intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P190018 ↗ |
| Jun 18, 2025 | AcrySof IQ ReSTOR Posterior Chamber Intraocular Lenses Lens, multifocal intraocular | ALC Alcon Research, Ltd. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P040020 ↗ |
| May 28, 2025 | TRYPTYR ACOLTREMON | ALC Alcon Labs Inc | New drug (NDA) Type 1 - New Molecular Entity | NDA217370 ↗ |
| May 2, 2025 | CYCLOMYDRIL CYCLOPENTOLATE HYDROCHLORIDE; PHENYLEPHRINE HYDROCHLORIDE | ALC Alcon Labs Inc | Generic (ANDA), supplement Labeling | ANDA084300 ↗ |
| Apr 28, 2025 | LenSx Laser System (8065998162) | ALC Alcon Laboratories, Inc. | Device clearance (510(k)) Traditional | K243896 ↗ |
| Apr 15, 2025 | PATADAY ONCE DAILY RELIEF OLOPATADINE HYDROCHLORIDE | ALC Alcon Labs Inc | New drug (NDA), supplement Labeling | NDA206276 ↗ Letter or label ↗ |
| Apr 15, 2025 | PATADAY ONCE DAILY RELIEF OLOPATADINE HYDROCHLORIDE | ALC Alcon Labs Inc | New drug (NDA), supplement Labeling | NDA021545 ↗ Letter or label ↗ |
| Apr 15, 2025 | PATADAY TWICE A DAY RELIEF OLOPATADINE HYDROCHLORIDE | ALC Alcon Labs Inc | New drug (NDA), supplement Labeling | NDA020688 ↗ Letter or label ↗ |
| Mar 21, 2025 | AcrySof Posterior Chamber Intraocular Lenses intraocular lens | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P930014 ↗ |
| Mar 13, 2025 | PHENYLEPHRINE HYDROCHLORIDE PHENYLEPHRINE HYDROCHLORIDE | ALC Alcon | New drug (NDA), supplement Manufacturing (CMC) | NDA207926 ↗ |
| Mar 5, 2025 | WaveLight EX500 Laser Excimer laser system | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement Panel Track | P020050 ↗ |
| Jan 30, 2025 | Hydrus Microstent Intraocular pressure lowering implant | ALC Alcon Research, LLC | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P170034 ↗ |
| Jan 24, 2025 | ROCKLATAN LATANOPROST; NETARSUDIL DIMESYLATE | ALC Alcon Labs Inc | New drug (NDA), supplement Labeling | NDA208259 ↗ |
| Jan 16, 2025 | WaveLight EX500 Laser System Excimer laser system | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement Real-Time Process | P030008 ↗ |
| Jan 16, 2025 | WaveLight EX500 Laser System Excimer laser system | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement Real-Time Process | P020050 ↗ |
| Jan 13, 2025 | Precision1; Precision1 for Astigmatism; Dailies Total1; Dai… | ALC Alcon Laboratories, Inc. | Device clearance (510(k)) Special | K243909 ↗ |
| Dec 16, 2024 | Clareon Toric Aspheric Hydrophobic Acrylic Intraocular Lens… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Real-Time Process | P190018 ↗ |
| Dec 4, 2024 | Alcon 27GA Chandelier (8065000252); Alcon 27+ DS Wide Angle… | ALC Alcon Laboratories, Inc. | Device clearance (510(k)) Traditional | K242184 ↗ |
| Sep 18, 2024 | RHOPRESSA NETARSUDIL MESYLATE | ALC Alcon Labs Inc | New drug (NDA), supplement Labeling | NDA208254 ↗ |
| Aug 28, 2024 | Hydrus® Microstent Intraocular pressure lowering implant | ALC Alcon Research, LLC | Device approval (PMA), supplement Normal 180 Day Track No User Fee | P170034 ↗ |
| Aug 26, 2024 | UNIPURE SF6 Ophthalmic Gas in the UNIFEYE Gas Delivery Syst… Gases used within eye to place pressure on detached retina | ALC Alcon Research, LLC | Device approval (PMA) | P230012 ↗ |
| Jul 12, 2024 | AcrySof® Posterior Chamber Intraocular Lens and Delivery Sy… intraocular lens | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P930014 ↗ |
| Jul 12, 2024 | Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL)… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P190018 ↗ |
| Jul 12, 2024 | AcrySof® ReSTOR Apodized Diffractive Optic Posterior Chambe… Lens, multifocal intraocular | ALC Alcon Research, Ltd. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P040020 ↗ |
| Jul 2, 2024 | UNIPURE C3F8 Ophthalmic Gas in the UNIFEYE Gas Delivery Sys… Gases used within eye to place pressure on detached retina | ALC Alcon Research, LLC | Device approval (PMA) | P220030 ↗ |
| Jun 21, 2024 | UNITY VCS (8065000296); UNITY CS (8065000297) | ALC Alcon Laboratories, Inc. | Device clearance (510(k)) Traditional | K233876 ↗ |
| May 30, 2024 | PROPARACAINE HYDROCHLORIDE, ALCAINE PROPARACAINE HYDROCHLORIDE | ALC Alcon Labs Inc | Generic (ANDA), supplement Labeling | ANDA080027 ↗ |
| May 29, 2024 | AcrySof® Posterior Chamber Intraocular Lens and Delivery Sy… intraocular lens | ALC Alcon Laboratories, Inc. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P930014 ↗ |
| May 29, 2024 | Clareon Aspheric Hydrophobic Acrylic Intraocular Lens (IOL)… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P190018 ↗ |
| May 29, 2024 | AcrySof® IQ ReSTOR® Posterior Chamber Intraocular Lenses Lens, multifocal intraocular | ALC Alcon Research, Ltd. | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P040020 ↗ |
| May 21, 2024 | Clareon Vivity Extended Vision Hydrophobic Intraocular Len… intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Normal 180 Day Track | P190018 ↗ |
| Apr 30, 2024 | Hydrus® Microstent Intraocular pressure lowering implant | ALC Alcon Research, LLC | Device approval (PMA), supplement 135 Review Track For 30-Day Notice | P170034 ↗ |
| Mar 5, 2024 | Clareon PanOptix Pro Trifocal IOLs intraocular lens | ALC Alcon Laboratories, LLC | Device approval (PMA), supplement Real-Time Process | P190018 ↗ |
The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 5:56 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates